Clinical implications of molecular heterogeneity in triple negative breast cancer

被引：91
作者：
Lehmann, Brian D. [1 ]
Pietenpol, Jennifer A. [1 ]
机构：
[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Biochem, Nashville, TN 37232 USA
来源：
BREAST | 2015年 / 24卷
关键词：
Chemotherapy; TNBCtype; Neoadjuvant; PIK3CA; Androgen receptor; TUMOR-INFILTRATING LYMPHOCYTES; COMPLETE RESPONSE RATES; NEOADJUVANT CHEMOTHERAPY; PHASE-II; STAGE-II; CARBOPLATIN; BEVACIZUMAB; EXPRESSION; MUTATIONS; SUBTYPES;
D O I：
10.1016/j.breast.2015.07.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Triple negative breast cancer (TNBC) is a molecularly heterogeneous disease lacking recurrent targetable alterations and thus therapeutic advances have been challenging. The absence of ER, PR and HER2 amplifications, leaves combination chemotherapy as the standard of care treatment option in the adjuvant, neoadjuvant and metastatic settings. Recently, multiple studies have shed some light on the heterogeneity of TNBC and identified distinct transcriptional subtypes with unique biologies. Herein we review the molecular heterogeneity and the impact on previous and future clinical trials. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码：S36 / S40
页数：5
相关论文
共 55 条
  • [1] Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
    Adams, Sylvia
    Gray, Robert J.
    Demaria, Sandra
    Goldstein, Lori
    Perez, Edith A.
    Shulman, Lawrence N.
    Martino, Silvana
    Wang, Molin
    Jones, Vicky E.
    Saphner, Thomas J.
    Wolff, Antonio C.
    Wood, William C.
    Davidson, Nancy E.
    Sledge, George W.
    Sparano, Joseph A.
    Badve, Sunil S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) : 2959 - +
  • [2] Higher Population-Based Incidence Rates of Triple-Negative Breast Cancer Among Young African-American Women Implications for Breast Cancer Screening Recommendations
    Amirikia, Kathryn C.
    Mills, Paul
    Bush, Jason
    Newman, Lisa A.
    [J]. CANCER, 2011, 117 (12) : 2747 - 2753
  • [3] Pembrolizumab Shows Potential in Breast Cancer
    不详
    [J]. CANCER DISCOVERY, 2015, 5 (02) : 100 - 101
  • [4] [Anonymous], SAN ANTONIO BREAST C
  • [5] Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
    Balko, Justin M.
    Giltnane, Jennifer M.
    Wang, Kai
    Schwarz, Luis J.
    Young, Christian D.
    Cook, Rebecca S.
    Owens, Phillip
    Sanders, Melinda E.
    Kuba, Maria G.
    Sanchez, Violeta
    Kurupi, Richard
    Moore, Preston D.
    Pinto, Joseph A.
    Doimi, Franco D.
    Gomez, Henry
    Horiuchi, Dai
    Goga, Andrei
    Lehmann, Brian D.
    Bauer, Joshua A.
    Pietenpol, Jennifer A.
    Ross, Jeffrey S.
    Palmer, Gary A.
    Yelensky, Roman
    Cronin, Maureen
    Miller, Vincent A.
    Stephens, Phillip J.
    Arteaga, Carlos L.
    [J]. CANCER DISCOVERY, 2014, 4 (02) : 232 - 245
  • [6] Expression of VEGF and Semaphorin Genes Define Subgroups of Triple Negative Breast Cancer
    Bender, R. Joseph
    Mac Gabhann, Feilim
    [J]. PLOS ONE, 2013, 8 (05):
  • [7] Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses
    Brodowicz, T.
    Lang, I.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Petruzelka, L.
    Eniu, A.
    Anghel, R.
    Koynov, K.
    Vrbanec, D.
    Pienkowski, T.
    Melichar, B.
    Spanik, S.
    Ahlers, S.
    Messinger, D.
    Inbar, M. J.
    Zielinski, C.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 111 (11) : 2051 - 2057
  • [8] Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
    Burstein, Matthew D.
    Tsimelzon, Anna
    Poage, Graham M.
    Coyington, Kyle R.
    Contreras, Alejandro
    Fuqua, Suzanne A. W.
    Sayage, Michelle I.
    Osborne, C. Kent
    Hilsenbeck, Susan G.
    Chang, Jenny C.
    Mills, Gordon B.
    Lau, Ching C.
    Brown, Powel H.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1688 - 1698
  • [9] Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
    Byrski, Tomasz
    Gronwald, Jacek
    Huzarski, Tomasz
    Grzybowska, Ewa
    Budryk, Magdalena
    Stawicka, Malgorzata
    Mierzwa, Tomasz
    Szwiec, Marek
    Wisniowski, Rafal
    Siolek, Monika
    Dent, Rebecca
    Lubinski, Jan
    Narod, Steven
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 375 - 379
  • [10] Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Carey, Lisa A.
    Perou, Charles M.
    Livasy, Chad A.
    Dressler, Lynn G.
    Cowan, David
    Conway, Kathleen
    Karaca, Gamze
    Troester, Melissa A.
    Tse, Chiu Kit
    Edmiston, Sharon
    Deming, Sandra L.
    Geradts, Joseph
    Cheang, Maggie C. U.
    Nielsen, Torsten O.
    Moorman, Patricia G.
    Earp, H. Shelton
    Millikan, Robert C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21): : 2492 - 2502
123456